Corrigendum to ‘A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells’ [Journal of Controlled Release 149(2) (2011) 196–205]

IF 12.4 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Journal of Controlled Release Pub Date : 2026-04-10 Epub Date: 2026-02-09 DOI:10.1016/j.jconrel.2026.114675

Joanna Kopecka , Ivana Campia , Paolo Olivero , Gianpiero Pescarmona , Dario Ghigo , Amalia Bosia , Chiara Riganti

引用次数: 0

查看原文本刊更多论文

“低密度脂蛋白掩盖脂质体-阿霉素逆转人类癌细胞的耐药性”的更正[Journal of control Release 149(2) (2011) 196-205]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.